Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma

By LabMedica International staff writers
Posted on 20 Nov 2026

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma, an aggressive blood cancer. More...

However, nearly half of patients either fail to respond or relapse within a year, highlighting the need for reliable predictors of treatment outcomes. New findings suggest that a blood-based RNA test may help identify patients more likely to benefit from CAR T-cell therapy before treatment begins.

Researchers at Cornell University and Dana-Farber Cancer Institute identified a cell-free RNA (cfRNA) gene expression signature associated with response to chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma. The signature is derived from RNA fragments released into blood plasma by cells, potentially providing a noninvasive view of the tumor microenvironment. By capturing molecular signals from immune cells, structural cells, and blood vessel cells surrounding tumors, the approach may offer insights into treatment response without requiring tissue biopsies.

The study analyzed pretreatment plasma samples from 91 lymphoma patients receiving a specific CAR T-cell therapy product at Dana-Farber Cancer Institute. Participants, whose median age was 65, were evaluated across three separate groups. Researchers found that patients with higher scores for a lymph node-like gene expression signature were more likely to respond to treatment. Those with high signature scores also had an 80% lower risk of disease progression compared with patients with low scores.

The blood-based signature closely reflected findings from an earlier study that identified similar molecular patterns in tumor biopsy samples. Patients with above-median signature scores experienced significantly longer survival across all three groups, further supporting its potential prognostic value. Notably, the signature was absent from matched circulating immune cells, suggesting that plasma cfRNA captures biological activity within tumor-associated tissues rather than simply reflecting changes in the composition of circulating blood cells.

The study was published on November 18 in Cell Reports Medicine. Cornell University and Dana-Farber Cancer Institute collaborated on the work. The authors stated that the model requires validation in larger, multi-institution cohorts and that the findings have not been shown to change patient outcomes.

“CAR T-cell therapy is one of the major breakthroughs of the past couple of decades, but not every patient responds,” said Iwijn De Vlaminck, professor in the Meinig School of Biomedical Engineering in the Cornell Duffield College of Engineering. 

“The study was focused on a specific patient group. The next step would be to expand that to other patients who are receiving CAR T therapy. Next would be validating across a cohort and seeing if this is reproducible across different contexts,” said Glory Feyisayo Agun, a doctoral student in De Vlaminck’s lab.

Related Links
Cornell University
Dana-Farber Cancer Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.